HC Wainwright Reaffirms Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 401.25% from the stock’s current price.

ARTV has been the topic of several other reports. Cantor Fitzgerald lowered their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wedbush reissued an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $3.99 on Wednesday. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31. The company’s fifty day moving average price is $4.91 and its 200-day moving average price is $9.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the third quarter valued at $42,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Artiva Biotherapeutics by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock valued at $439,000 after acquiring an additional 3,233 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares during the last quarter. Northern Trust Corp grew its position in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares in the last quarter. Finally, Barclays PLC increased its stake in Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.